Sanofi's rivals in the insulin field are nipping at its heels – Lantus sales dipped 5 per cent in the first half of 2015, and analysts don't expect Toujeo to make up for its decline.

Sanofi's new insulin treatment Toujeo has shown its superiority in controlling blood sugar levels in patients in phase 3 trials. Toujeo is a new and improved formulation of Lantus (insulin ...

Your doctor will help you make a diabetes treatment plan that is right for you. Toujeo is an injectable insulin medication for the treatment of diabetes (type 1 or type 2) in people who are 6 ...

This should help Novo continue to gain share despite biosimilar Lantus (Lilly's Basaglar) and Sanofi's next-generation insulin, Toujeo. However, U.S. pricing headwinds are preventing growth in ...

The Chinese government's policies promoting opening up and innovation, as well as the excellent business environment it fosters for foreign enterprises, have injected strong confidence into Sanofi's ...